Our group previously demonstrated that PRIMA-1 prevents p53 aggregation and inhibits the prion-like effects of mutp53 in breast and ovarian cancer cells by reducing the levels of intracellular amyloid oligomers of R280K and R248Q p53 mutants along with the reactivation and restoration of WTp53 activity (Rangel et al., 2019). The gene discussed is TP53; the disease is ovarian carcinoma.